RxDoctor Payments Data

Naseer Nasser, MD

Interventional Cardiology · Michigan City, INNPI 1063436582

Payments from drug & device makers

$10,318in general payments, 2019–2025

Across 95 payments — averaging $108.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$3K
  • Medtronic$2K
  • Abiomed$302
  • Edwards Lifesciences$213
  • Novartis$103
  • plus $447 from 13 others

What the payments were for

  • Speaking & faculty fees$2,00019%
  • Travel & lodging$5,35752%
  • Food & beverage$2,68526%
  • Education$2763%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,318 in reported general payments places this provider in the 55th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$364,858
Medicare patients
1,334
Services billed
4,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$83,066
XareltoRivaroxaban63$78,329
EntrestoSacubitril/Valsartan24$35,237
BrilintaTicagrelor26$18,209
Flecainide Acetate44$3,679
Amiodarone Hcl44$3,217
Varenicline Tartrate24$2,924
Dofetilide23$2,770
ClopidogrelClopidogrel Bisulfate166$1,578
Prasugrel Hcl19$1,556
Metoprolol Succinate125$1,433
Atorvastatin Calcium108$1,249
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$871
Propafenone Hcl14$650
Carvedilol54$549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$83,06674 claims
NovartisEntresto$103$35,23724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →